Pharmacological properties of abiraterone acetate (ZYTIGA<sup>®</sup> tablet 250 mg), a new drug for the treatment of castration-resistant prostate cancer, and results of its clinical studies
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.